Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review

Date: June 22, 2017
Pages: 63
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: VE656B9CD2CEN
Leaflet:

Download PDF Leaflet

Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review
Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Valeant Pharmaceuticals International Inc (Valeant) is a pharmaceutical and medical device company that carries out development, manufacture and marketing of several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International Inc Key Recent Developments

Jun 22,2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
Jun 19,2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
Jun 19,2017: John Paulson Joins Valeant Board Of Directors
May 22,2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution
May 09,2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Valeant Pharmaceuticals International Inc - Key Facts
Valeant Pharmaceuticals International Inc - Key Employees
Valeant Pharmaceuticals International Inc - Key Employee Biographies
Valeant Pharmaceuticals International Inc - Major Products and Services
Valeant Pharmaceuticals International Inc - History
Valeant Pharmaceuticals International Inc - Company Statement
Valeant Pharmaceuticals International Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Valeant Pharmaceuticals International Inc - Business Description
Valeant Pharmaceuticals International Inc - Corporate Strategy
Valeant Pharmaceuticals International Inc - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International Inc - Strengths
Valeant Pharmaceuticals International Inc - Weaknesses
Valeant Pharmaceuticals International Inc - Opportunities
Valeant Pharmaceuticals International Inc - Threats
Valeant Pharmaceuticals International Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Valeant Pharmaceuticals International Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors
May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution
May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
Feb 27, 2017: Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors
Dec 21, 2016: Collins, McCaskill Release Committee Report of Bipartisan Drug Pricing Investigation
Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Valeant Pharmaceuticals International Inc, Key Facts
Valeant Pharmaceuticals International Inc, Key Employees
Valeant Pharmaceuticals International Inc, Key Employee Biographies
Valeant Pharmaceuticals International Inc, Major Products and Services
Valeant Pharmaceuticals International Inc, History
Valeant Pharmaceuticals International Inc, Other Locations
Valeant Pharmaceuticals International Inc, Subsidiaries
Valeant Pharmaceuticals International Inc, Key Competitors
Valeant Pharmaceuticals International Inc, Ratios based on current share price
Valeant Pharmaceuticals International Inc, Annual Ratios
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont...1)
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont...2)
Valeant Pharmaceuticals International Inc, Interim Ratios
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Valeant Pharmaceuticals International Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Valeant Pharmaceuticals International Inc, Performance Chart (2012 - 2016)
Valeant Pharmaceuticals International Inc, Ratio Charts
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Xenon Pharmaceuticals Inc
Stratus Pharmaceuticals Inc
Sirona Biochem Corp
Polydex Pharmaceuticals Ltd
Pfizer Canada Inc
Opiant Pharmaceuticals Inc
Mylan NV
Maruho Co Ltd
GTx Inc
Endo International Plc
AIM Therapeutics Inc
Skip to top


Ask Your Question

Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: